Etiket: Hodgkins
ADC Therapeutics announces results from a pivotal Phase II clinical trial of camidanlumab tesirine (Cami) in patients with relapsed or refractory Hodgkin’s lymphoma
shares in this article ADC Therapeutics SA (NYSE: ADCT) today announced results from its ongoing pivotal Phase II clinical trial of camidanlumab tesirine (Cami) in patients with relapsed or refractory…